Department of Radiology, University Hospitals of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland.
Hepato-Pancreato-Biliary Centre, University Hospitals of Geneva, Geneva, Switzerland.
Eur Radiol. 2018 Nov;28(11):4810-4817. doi: 10.1007/s00330-018-5476-1. Epub 2018 May 22.
To evaluate the safety and efficacy of ethylene vinyl alcohol copolymer (EVOH) injection for selective occlusion of portal branches considered at risk for non-target embolisation during preoperative portal vein embolisation (PVE).
Twenty-nine patients (mean age, 57 ± 17 years) submitted to PVE with n-butyl-cyanoacrylate (NBCA) and additional EVOH for selected portal branches were retrospectively analysed. Indications for the use of EVOH and the selected portal branches were evaluated. Degree of hypertrophy of the future liver remnant (FLR) and kinetic growth were assessed by CT volumetry performed before and 3-6 weeks after PVE. Clinical outcome and histopathological analysis of portal veins occluded with EVOH were reviewed.
EVOH was indicated intraoperatively for embolisation of selected portal branches that the operator reported at risk to provoke non-target embolisation with NBCA. Indications for the use of EVOH were embolisation of segment IV (n = 21), embolisation of segmental portal branches with early bifurcation (n = 7) and PVE in a 1-year-old girl with cystic hamartomas. All targeted portal branches were successfully embolised. There were no cases with non-target embolisation by EVOH. The degree of hypertrophy of the FLR was 14.3 ± 8.1% and the kinetic growth rate was 2.7 ± 1.8% per week.
EVOH is safe and effective for embolisation of selected portal vein branches considered at risk for non-target embolisation.
• EVOH is another effective liquid embolic agent for preoperative PVE. • EVOH is relatively simple to handle with a minimal risk of non-target embolisation. • During PVE, some portal branches considered complicated to occlude with NBCA may be efficiently embolised with EVOH.
评估乙烯-乙烯醇共聚物(EVOH)注射用于选择性阻断门静脉栓塞术(PVE)前因非目标栓塞风险而被视为高危的门静脉分支的安全性和有效性。
回顾性分析了 29 例接受 n-丁基-氰基丙烯酸酯(NBCA)和额外 EVOH 选择性栓塞部分门静脉分支的 PVE 患者。评估了使用 EVOH 和选择的门静脉分支的适应证。通过 PVE 前和 3-6 周后的 CT 体积测量评估未来肝脏残余(FLR)的肥大程度和动力学生长。回顾性分析了用 EVOH 闭塞的门静脉的临床结果和组织病理学分析。
EVOH 术中用于栓塞术者报告有引发 NBCA 非目标栓塞风险的部分门静脉分支。使用 EVOH 的适应证为栓塞 IV 段(n = 21)、早期分叉的节段性门静脉分支(n = 7)和 1 岁女孩囊性错构瘤的 PVE。所有目标门静脉分支均成功栓塞。没有 EVOH 导致非目标栓塞的病例。FLR 的肥大程度为 14.3±8.1%,动力学生长速度为每周 2.7±1.8%。
EVOH 安全、有效,可用于栓塞被认为有非目标栓塞风险的选择性门静脉分支。
EVOH 是术前 PVE 的另一种有效的液体栓塞剂。
EVOH 相对容易处理,非目标栓塞的风险较小。
在 PVE 期间,一些用 NBCA 难以栓塞的门静脉分支可以用 EVOH 有效地栓塞。